| DEPARTMENT OF HEALTH AND HUMAN SERVICES | | | | | |
|--|------------------------------|--|--|--|--|
| FOOD AND DRUG ADMINISTRATION | | | | | |
| DISTRICT ADDRESS AND PHONE NUMBER | DATE(S) OF INSPECTION | | | | |
| | | | | | |
| 300 River Place, Suite 5900 | 08/25/2005 - 09/12/2005* | | | | |
| Detroit, MI 48207 | FELNUMBER | | | | |
| (313) 393-8100 Fax: (313) 393-8139 | 1828132 | | | | |
| NAME AND TITLE OF INCIVIDUAL TO WHOM REPORT ISSUED | | | | | |
| TO: Mr. George Telthorst, General Manager | | | | | |
| FIRM NAME | STREET ACCRESS | | | | |
| Boston Scientific Corp | 780 Brookside Dr | | | | |
| CITY, STATE, ZP CCDE, COUNTRY | TYPE ESTABLISHMENT INSPECTED | | | | |
| Spencer, IN 47460-1080 | Medical Device Manufacturer | | | | |

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

The observations noted in this Form FDA-483 are not an exhaustive listing of objectionable conditions. Under the law, your firm is responsible for conducting internal self-audits to identify and correct any and all violations of the quality system requirements.

DURING AN INSPECTION OF YOUR FIRM I OBSERVED:

OBSERVATION 1

An MDR report was not submitted within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a marketed device has malfunctioned and would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.

Specifically, Complaints are received by the Boston Scientific Complaint Call Center, who then forwards the complaint to the appropriate Complaint Management Center (CMC), where an initial MDR determination is completed. The CMC then has the Complaint Investigation Site, the site that manufactured the device, conduct a complaint investigation to determine root cause and search for complaint trends. The following complaints were determined to be MDR reportable by Boston Scientific Corporation, however, the MDR reports were filed more than 30 days after the initial complaint notification.

| Complaint # | Date | MDR Date | MDR # | Total Days to Report |
|-------------|---------|----------|--------------------|----------------------|
| 656079 | 4/12/05 | 5/27/05 | 6000048-2005-00069 | 45 |
| 650818 | 12/9/05 | 1/28/05 | 6000048-2005-00011 | 50 |
| 658865 | 6/20/05 | 8/10/05 | 6000048-2005-00100 | 51 |
| 652641 | 1/31/05 | 7/25/05 | 6000043-2005-00028 | 176 |
| 655395 | 4/1/05 | 6/30/05 | 6000043-2005-00021 | 90 |
| 654226 | 2/28/05 | 6/30/05 | 6000043-2005-00020 | 122 |
| 646103 | 8/16/04 | 2/10/05 | 6000043-2005-00002 | 178 |
| 647525 | 9/21/04 | 2/10/05 | 6000043-2005-00008 | 142 |
| 645897 | 8/2/04 | 2/10/05 | 6000043-2005-00003 | 192 |
| 649232 | 11/1/04 | 1/28/05 | 6000048-2005-00013 | 10 |
| 655419 | 4/4/05 | 6/30/05 | 6000043-2005-00023 | 90 |
| 652411 | 1/25/05 | 3/21/05 | 6000043-2005-00014 | 55 |
| 646545 | 8/25/04 | 2/28/05 | 6000043-2005-00006 | 84 |
| | | | | · |

This is a modified document.

SEE REVERSE
OF THIS PAGE

O9/12/2005

FORM FDA 483 (07.00)

PREVIOUS FORTION OBSOLUTE

INSPECTIONAL OBSERVATIONS

PAGE 1 OF 3 PAGES

| DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION | | | | | | |
|--|------------------------------|------------------|--|--|--|--|
| DISTRICT ADDRESS AND PHONE NUMBER | DATE(S) OF INSPECTICY | | | | | |
| 300 River Place, Suite 5900 | 08/25/2005 - 09/3 | 12/2005* | | | | |
| Detroit, MI 48207 | FEI NUMBER | | | | | |
| (313) 393-8100 Fax: (313) 393-8139 1828132 | | | | | | |
| NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED | | | | | | |
| TO: Mr. George Telthorst, Genera | | | | | | |
| FIRM NAME | STREET ADDRESS | STREET ADDRESS | | | | |
| Boston Scientific Corp | 780 Brookside Dr | 780 Brookside Dr | | | | |
| CITY, STATE, ZIP CODE, COUNTRY | TYPE ESTABLISHMENT INSPECTED | | | | | |
| Spencer, IN 47460-1080 | Medical Device Manufacturer | | | | | |
| 648630 10/18/042/28/05 | 6000043-2005-00005 41 | | | | | |
| 647742 9/27/04 2/28/05 | 6000043-2005-00004 154 | | | | | |
| 627223 5/7/05 6/30/05 | 6000043-2005-00022 54 | | | | | |
| | | | | | | |

OBSERVATION 2

Complaints involving the possible failure of a device to meet any of its specifications were not evaluated and investigated where necessary.

Specifically,

- a) The LeVeen Needle Electrode recall investigation was incomplete. BSC Spencer, the manufacturer of the LeVeen Needle Electrode, which is used as an accessory in conjunction with the Boston Scientific Corporations Radiofrequency (RF) generator for thermal necrosis of soft tissues, was not aware of the LeVeen Needle Electrode recall when the FDA Investigator asked for that specific recall documentation. By not being aware of the LeVeen Needle Electrode recall and the subsequent investigation activities, the firm can not assure that a complete recall investigation was conducted on both the LeVeen Needle Electrode, manufactured at BSC Spencer, and the BSC RF generator. The product investigation report is WAT-2005-04-01. The LeVeen Needle Electrode affected model numbers are M001262160 and M001262170.
- b) BSC Spencer has the capability to do trending analysis by product lot number and product part number. For 7 of 15 complaints reviewed specific to the Leveen Electrode recall, Part #M001262160 and M001262170, Complaints 656988, 654015, 654019, 654023, 654029, 654032, 654033 the device was not returned and the complainant did not give the lot number. The complaint investigation was incomplete in that the firm did not investigate each complaint completely to identify possible trends. For these seven complaints, the lot number was not available and there was no trending analysis done on the LeVeen product number.

OBSERVATION 3

Complaint handling procedures for reviewing and evaluating complaints have not been completed.

Specifically, BSC Spencer External Customer Complaint Process procedure, #90101079 is incomplete in that it does not identify all trending types to be researched during the failure analysis to determine if their are any related complaints. For 7 of 15 complaints reviewed specific to the Leveen Electrode recall, the firm did not do trending by product part number for complaint investigations when the device was not returned and the firm was unable to obtain the product lot number. The complaints were closed after 90 days.

| | | DATE ISSUED |
|-----------------------------|-----|-------------|
| SEE REVERSE OF THIS PAGE | BIS | 09/12/2005 |

FORM FDA 481 (07/00) PREVIOUS EDITION OBSOLUTE INSPECTIONAL OBSERVATIONS PAGE 2 OF 3 PAGES

| DEPARTMENT OF HEALTH AND HUMAN SERVICES | | | | | |
|--|------------------------------|--|--|--|--|
| FOOD AND DRUG ADMINISTRATION DISTRICT ADDRESS AND PHONE NUMBER CATE(S) OF INSPECTION | | | | | |
| DISTRICT ADDRESS AND PROPE NUMBER | DATE(S) OF INSPECTION | | | | |
| 300 River Place, Suite 5900 | 08/25/2005 - 09/12/2005* | | | | |
| Detroit, MI 48207 | FEI NUMBER | | | | |
| (313) 393-8100 Fax: (313) 393-8139 | 1828132 | | | | |
| NAME AND TITLE OF HOWIDUAL TO WHOM REPORT ISSUED | | | | | |
| TO: Mr. George Telthorst, General Manager | | | | | |
| FIRM HAME | STREET ADDRESS | | | | |
| Boston Scientific Corp | 780 Brookside Dr | | | | |
| CHY, STATE VEP COOLE, COUNTRY | TYPE ESTABLISHMENT INSPECTED | | | | |
| Spencer, IN 47460-1080 | Medical Device Manufacturer | | | | |
| | | | | | |

OBSERVATION 4

Procedures for the control and distribution of finished devices have not been defined and complete to ensure that only devices approved for release are distributed.

Specifically, when BSC Spencer places a shipping hold on products, they can still ship product from their facility to the BSC Quincy distribution facility "at risk" and on ship hold. The BSC Spencer procedure, Shipping Holds - In-plant and Distribution Holds, Q489027-0A, does not require the firm to hold product at the BSC Spencer facility.

* DATES OF INSPECTION:

08/25/2005(Thu), 08/26/2005(Fri), 08/29/2005(Mon), 08/30/2005(Tue), 09/02/2005(Fri), 09/06/2005(Tue), 09/09/2005(Fri), 09/12/2005(Mon)

FDA EMPLOYEE'S NAME, TITLE, AND SIGNATURE:

Benjamin J Smith, Investigator

SEE REVERSE
OF THIS PAGE

O9/12/2005